Revolutionizing Medicine: Rani Therapeutics secures $10 million in funding for groundbreaking RaniPill™ technology

Rani Therapeutics, a pioneering clinical-stage biotech company, is thrilled to announce the successful closure of a $10 million funding round aimed at further advancing its innovative oral biologic drug delivery platform. The company has developed the RaniPill™ technology, a groundbreaking solution that enables the oral administration of biologics, traditionally requiring painful injections. This advancement is crucial for the millions of patients suffering from chronic conditions who depend on injectable medications. The RaniPill™ capsule delivers biologics directly to the intestinal wall, an area free from sharp pain receptors, achieving bioavailability comparable to that of subcutaneous injections. With this new influx of capital, Rani Therapeutics plans to accelerate its clinical trials and expand its product offerings, ultimately providing enhanced treatment options that prioritize patient comfort and convenience. The funding will also enable Rani Therapeutics to expand its research and development team, ensuring that it stays at the forefront of innovation in the biotech industry. By creating oral alternatives to injections, Rani Therapeutics aims to transform the landscape of medicine, making it possible for patients to manage their conditions without the need for daily self-injections. This funding milestone not only reflects confidence in Rani's vision to improve patient outcomes, but also bolsters its commitment to delivering safer, easier, and more effective therapeutic solutions for those who require biologic therapies. As the company looks to the future, it remains focused on its mission to revolutionize the ways in which biologic drugs can be administered and to enhance the lives of millions around the world.